Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy

AIDS

Volumn 13, Issue 11, 1999, Pages 1337-1342

  Pilcher, Christopher D ^a   Miller, William C ^a,b   Beatty, Zoe A ^a,b   Eron, Joseph J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

Antiretroviral therapy; HIV diagnostic tests; HIV infection; Prognosis; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RELAPSE; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAGENT KITS, DIAGNOSTIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 0032817872     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907300-00010     Document Type: Article

References (16)

1. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997,126:946-954.
2. + lymphocyte counts and the risk of progression to AIDS. NEnglJMed 1996, 334:426-454.
3. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996, 174:704-712.
4. Demeter L, Hughes M, Fischl M, et al. Predictors of virologie and clinical responses to indinavir (IDV) + ZDV + 3TC or ZDV +3 TC. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998 [abstract 509].
5. Katzenstein DA, Hammer SM, Hughes MD, for the AIDS Clinical Trials Croup Study 175 Virology Study Team. The relation of virologie and immunologie markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Eng! l Med 1996, 335:1091-1098.
6. Phillips AN, Eron JJ, Bartlett JA, et al. HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. AIDS 1996, 10:859-865.
7. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998, 12:F9-F14.
8. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998, 280:78-86.
9. Bremer JVV, Brambilla D, Staes B, for the DAIDS-Sponsored Virology Laboratories. Performance of HIV RNA quantitation assays on HIV-negative specimens. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, 1998 [abstract 317].
10. Harrell FE, Jr. Predicting Outcomes: Applied Survival Analysis and Logistic Regression. Charlottesville, VA: University of Virginia; 1997.
11. Robinson P, Montaner JSC. Long-term follow-up of patients treated with nevirapine (NVP) based combination therapy within the INCAS trial. XII International Conference on AIDS. Geneva, June 1998 (abstract 123681.
12. Kahn J, Mayers D, Riddler S, et al. Durable clinical anti-HIV-1 activity (60 weeks) and tolerability for efavirenz (DMP-266) in combination with indinavir (IDV): suppression to "<1 copy/ml" (OD = Background) by Amplicor as a predictor of virologie treatment response [DMP266-003, Cohort IV]. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, 1998 (abstract 692].
13. Drusano GL, Bilello JA, Stein DS. Factors influencing the emergence of resistance to indinavir: role of virologie, immunologie, and pharmacologie variables. J Infect Dis 1998, 178:360-367.
14. Gunthard HF, VVong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genolypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998, 72:2422-2428.
15. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
16. Hammer S, Crumpacker C, D'Aquila R, et al. Use of virologie assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee. J Clin Microbiol 1993, 31:2557-2564.